Coley's toxins in perspective
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite initial hopes, the efficacy of tumour necrosis factor in treating cancer patients has been disappointing. But a more careful selection of patients, and more appropriate treatment, might be fruitful.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in certain cases, injection of intratumoral bacteria or their antigens may conversely provide immunostimulatory effects, as demonstrated by Coley’s toxins and recent developments in bacterial cancer therapy (5, 105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [5]
Citations
Cites
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Goetz, F. (2004) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2003.09.008 · Cited by 301
Berendt, M. J., North, R. J., & Kirstein, D. P. (1978) · The Journal of Experimental Medicine · doi:10.1084/jem.148.6.1560 · Cited by 84
Prevalence of dysplasia and cancer of the cervix in a nationwide, planned parenthood population
Sadeghi, S. B., Sadeghi, A., & Robboy, S. J. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2219::aid-cncr2820611116>3.0.co;2-d · Cited by 58
Demetri, G. D., Spriggs, D. R., Sherman, M., Arthur, K. A., Imamura, K., & Kufe, D. W. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1545 · Cited by 57
Remarks upon the Effects Observed in the Use of Mixed Toxins (Coley) in Certain Cases of Sarcoma
Harmer, T. W. (1914) · New England Journal of Medicine · doi:10.1056/nejm191408131710701 · Cited by 4
Research works printed but not linked: 4
- Coley, W. B. Practitioner 83, 589–613 (1909).
- Nauts, H. C. et al. Can. Res. 6, 205–216 (1946).
- Tichatschek, E. et al. Can. Immun. Immunother. 27, 278–282 (1988).
- McIntosh, J. K. et al. Can. Res. 49, 1408–1414 (1989).
Cited by
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
“The earliest case of cancer immunotherapy can be traced back to 1891, when William Coley, the father of immunotherapy, first attempted to leverage the immune system to treat cancer after noticing that mixtures of live and inactivated Streptococcus pyogenes and Serratia marcescens could cause tumor regression in sarcom…”
BackgroundPhotodynamic therapy and anti-tumour immunity
Castano, A. P., Mroz, P., & Hamblin, M. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1894 · Cited by 2,676
“Over 100 years ago a surgeon from New York, William Cole”
BackgroundTumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
“The failure of TNF treatment prompted Charlie Starnes to revisit Coley's work in a 1992 Nature revie”
BackgroundSchwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
“Shortly thereafter, William Coley started testing a highly contentious and sometimes lethal vaccine of live or heat-killed Streptococcus and Serratia species on terminal cancer patients, which was only later shown to yield >10-year disease-free survival in ~30%of them (60 of 210 total), representing the first intentio…”
BackgroundInterleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy, E. F. (2006) · Europe PMC (PubMed Central) · Cited by 747
CD8 + T‐cell memory in tumor immunology and immunotherapy
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511
“’ – Leo Tolstoy For over a century, the prospect of employing a patient’s immune system to treat cancer has been the source of much hope and promise, yet at the same time frustration and dismay (1).”
Background(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
“promoted as the first intentional demonstration of immunotherapy and promoted.(10,13,14) In the 1900s, Thomas Glover and Virginia Livingston-Wheeler claimed that bacteria could be grown from tumors and suggested a common bacterial origin for cancer, but ultimately proved their theories incorrect.”
BackgroundDr William Coley and tumour regression: a place in history or in the future
Hoption Cann, S. A., van Netten, J. P., & van Netten, C. (2003) · Postgraduate Medical Journal · doi:10.1093/postgradmedj/79.938.672 · Cited by 433
Tumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386
The Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Bacterial CpG DNA Activates Immune Cells to Signal Infectious Danger
Wagner, H. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60790-7 · Cited by 314
Bacterial lipopolysaccharides and innate immunity
Alexander, C., & Rietschel, E. T. (2001) · Journal of Endotoxin Research · doi:10.1179/096805101101532675 · Cited by 1,120
Which cell death modality wins the contest for photodynamic therapy of cancer?
Mishchenko, T., Balalaeva, I., Gorokhova, A., Vedunova, M., & Krysko, D. V. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04851-4 · Cited by 276
“Coley discovered the positive effect of a “vaccine” based on a mixture of killed erysipelas-causing bacteria (nowadays called Coley’s toxins) in patients with non-operable sarcomas in the 19th century [18, 19], but it was only in 1994 that Polly Matzinger proposed the “danger theory” [20, 21].”
BackgroundNanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Fan, Y., & Moon, J. (2015) · Vaccines · doi:10.3390/vaccines3030662 · Cited by 275
“Coley successfully treated his cancer patients with bacterial products, which are now recognized to have induced non-specific anti-tumor inflammation [1].”
BackgroundDifferentiation and Definition of Vascular-Targeted Therapies
Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Horsman, M. R., Marmé, D., & LoRusso, P. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.416.11.2 · Cited by 272
The skin microbiome: Current perspectives and future challenges
Chen, Y. E., & Tsao, H. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.01.016 · Cited by 268
“On the other hand, acute inflammation can activate tumor necrosis factor and IL-12-induced antitumor activity, as in the case of Coley toxin causing sarcoma regression.(129,130) Commensal skin bacteria have been shown to both reduce inflammation during wound healing(131) and activate innate immunity and inflammatory c…”
BackgroundDecker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimarães, F., Burt, B. M., Kheradmand, F., & Paust, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00829 · Cited by 246
Cancer vaccines and carbohydrate epitopes
Heimburg-Molinaro, J., Lum, M., Vijay, G., Jain, M., Almogren, A., & Rittenhouse-Olson, K. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.09.009 · Cited by 227
“Cancer immunotherapy began in 1892, when Coley noticed that patients with cancer who developed a skin infection with Group A streptococcus called erysipelas sometimes experienced regression of their tumor [1–3].”
BackgroundInnate Immunity and Cancer Pathophysiology
Maiorino, L., Daßler-Plenker, J., Sun, L., & Egeblad, M. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032221-115501 · Cited by 215
Fusobacterium nucleatum and cancer
Alon‐Maimon, T., Mandelboim, O., & Bachrach, G. (2022) · Periodontology 2000 · doi:10.1111/prd.12426 · Cited by 194
Roles of the immune system in skin cancer
Rangwala, S., & Tsai, K. Y. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10507.x · Cited by 189
Antivascular therapy of cancer: DMXAA
Baguley, B. C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01018-0 · Cited by 187
Breakthrough of solid tumor treatment: CAR-NK immunotherapy
Wang, W., Liu, Y., He, Z., Li, L., Liu, S., Jiang, M., Zhao, B., Deng, M., Wang, W., Mi, X., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01815-9 · Cited by 172
Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses
Clausen, B. E., & Stoitzner, P. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00534 · Cited by 170
“From the time of the experiments of William Coley in the early 1900s immunotherapy of cancer was in the minds of immunologists (176), though it played a rather marginal role.”
BackgroundTumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 168
The effect of physical exercise on anticancer immunity
Fiuza‐Luces, C., Valenzuela, P. L., Gálvez, B. G., Ramírez, M. R., López‐Soto, A., Simpson, R. J., & Lucía, A. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00943-0 · Cited by 180
“Virchow had identified in 1863 that neoplastic tissues were often infiltrated with leucocytes 149 , and William Coley (often referred to as the ‘the father of immunotherapy’) had attempted to leverage the immune system to treat cancer in 1891 150,151 .”
Cancer immunotherapies, their safety and toxicity
Alatrash, G., Jakher, H., Stafford, P., & Mittendorf, E. A. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.795944 · Cited by 164
“Coley’s toxins eliminated some cancers, especially sarcomas, and were subsequently used for many decades [1].”
BackgroundVascular disrupting agents: a new class of drug in cancer therapy
Gaya, A. M., & Rustin, G. J. S. (2005) · Clinical Oncology · doi:10.1016/j.clon.2004.11.011 · Cited by 145
Rational approaches to human cancer immunotherapy
Davis, I. D., Jefford, M., Parente, P., & Cebon, J. S. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0502261 · Cited by 155
“and eventually over 800 [5].”
Toll-like receptors, wound healing, and carcinogenesis
Kluwe, J., Mencin, A., & Schwabe, R. F. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0426-z · Cited by 134
“Coley observed a considerable rate of tumor regression and even complete cure in larger sets of patients with sarcomas of the bone using “Coley’s toxin,” a mixture of heat-killed Streptococci and heat-killed Serratia marracens [73–75].”
BackgroundThe Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy
Xu, Z., Li, P., Fan, L., & Wu, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00009 · Cited by 139
“However, immunotherapy is not satisfactory as a result of tumor heterogeneity, and side effects still exist (26).”
BackgroundMethodToll-like Receptors in Tumor Immunotherapy
Paulos, C. M., Kaiser, A., Wrzesinski, C., Hinrichs, C. S., Cassard, L., Boni, A., Muranski, P. J., Sanchez-Perez, L. A., Palmer, D. C., Yu, Z., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1378 · Cited by 136
“Subsequent investigators, however, failed to reproduce these findings (2).”
Targeting Toll-Like Receptors for Cancer Therapy
Braunstein, M. J., Kucharczyk, J. R., & Adams, S. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0589-7 · Cited by 122
Cancer Immunotherapy: Sipuleucel‐T and Beyond
Hammerstrom, A. E., Cauley, D. H., Atkinson, B. J., & Sharma, P. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.8.813 · Cited by 123
Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application
Zhang, L., Xu, X., & Su, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01154-0 · Cited by 118
Zhou, T., Sankin, A. I., Porcelli, S. A., Perlin, D. S., Schoenberg, M., & Zang, X. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.004 · Cited by 119
“Coley reported regression of an inoperable sarcoma in a young girl who developed a superficial streptococcal infection [3].”
BackgroundNeoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
Wirth, T. C., & Kühnel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01848 · Cited by 98
“Since this was probably the first documented attempt to engage the patient’s immune system in the fight against cancer, William Coley has been referred to as the “father of cancer immunotherapy” (3).”
BackgroundPromising dawn in tumor microenvironment therapy: engineering oral bacteria
Wang, Z., Sun, W., Hua, R., Wang, Y., Li, Y., & Zhang, H. (2024) · International Journal of Oral Science · doi:10.1038/s41368-024-00282-3 · Cited by 97
“94,95 The immune response caused by bacteria is taken seriously in the human body, particularly in local tumors.”
BackgroundOral delivery of bacteria: Basic principles and biomedical applications
Li, S., Jiang, W., Zheng, C., Shao, D., Liu, Y., Huang, S., Han, J., Ding, J., Tao, Y., & Li, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.011 · Cited by 97
Hutmacher, C., & Neri, D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.002 · Cited by 99
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited
Decker, W. K., & Safdar, A. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.07.004 · Cited by 121
Tsung, K., & Norton, J. A. (2006) · Surgical Oncology · doi:10.1016/j.suronc.2006.05.002 · Cited by 92
“Further, approximately 20% of patients were cured and survived over 20 years [3].”
BackgroundInfluentialHemmerle, T., Probst, P., Giovannoni, L., Green, A. J., Meyer, T., & Neri, D. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.421 · Cited by 87
“This observation triggered the development of ‘Coley’s toxin’ (a mixture of heat-inactivated bacteria), which induced high fever in patients, but also a reasonable chance of long-term survival (Starnes, 1992).”
BackgroundIntratumor microbiome in cancer progression: current developments, challenges and future trends
Liu, J., & Zhang, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00381-5 · Cited by 80
Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer
Kappauf, H. W., Gallmeier, W. M., Wünsch, P. H., Mittelmeier, H. O., Birkmann, J., Büschel, G., Kaiser, G., & Kraus, J. (1997) · Annals of Oncology · doi:10.1023/a:1008209618128 · Cited by 78
Joseph, W. R., Cao, Z., Mountjoy, K. G., Marshall, E. S., Bc, B., & Ching, L.-M. (1999) · PubMed · Cited by 86
Kohchi, C., Inagawa, H., Nishizawa, T., Yamaguchi, T., Nagai, S., & Soma, G.-I. (2006) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.102.485 · Cited by 77
An overview of cancer immunotherapy
Davis, I. D. (2000) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2000.00906.x · Cited by 89
“Approximately half of these patients showed a good clinical response”
BackgroundTherapeutic Targeting of Signaling Pathways Related to Cancer Stemness
Espinosa-Sánchez, A., Suárez-Martínez, E., Sánchez-Díaz, L., & Carnero, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01533 · Cited by 71
“There are many pathways that regulate the CSC phenotype and its pluripotency state, providing mechanistic support for acquired drug resistance, including altered metabolism and oxidation states; phenotypic plasticity; increased membrane Frontiers in Oncology | www.frontiersin.org 20 August 2020 | Volume 10 | Article 1…”
BackgroundInfluentialTumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy
Yang, M., Zhou, J., Lu, L., Deng, D., Huang, J., Tang, Z., Shi, X., Lo, P., Lovell, J. F., Zheng, Y., et al. (2024) · Exploration · doi:10.1002/exp.20230171 · Cited by 89
Harnessing the Microbiome to Enhance Cancer Immunotherapy
Nelson, M. H., Diven, M. A., Huff, L. W., & Paulos, C. M. (2015) · Journal of Immunology Research · doi:10.1155/2015/368736 · Cited by 79
“In the late 19th centuryColey treated humanmalignancywith live bacterial cultures [10, 11].”
BackgroundThe interplay between the microbiome and the adaptive immune response in cancer development
Russo, E., Taddei, A., Ringressi, M. N., Ricci, F., & Amedei, A. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16635082 · Cited by 74
“In the past, antitumor effects were observed in patients with sarcomas, after the injection of heat killed bacteria or bacterial infections (termed Coley’s toxin) [Starnes, 1992].”
BackgroundXu, P., Tang, K., Ma, J., Zhang, H., Wang, D., Zhu, L., Chen, J., Wei, K., Liu, J., Fang, H., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0789 · Cited by 68
“Indeed, antitumor responses from neutrophils can be elicited by Coley toxin and Bacillus Calmette-Gu erin in certain patients with cancer (2, 3).”
BackgroundHeine, H., & Zamyatina, A. (2022) · Pharmaceuticals · doi:10.3390/ph16010023 · Cited by 80
Xin, R., Shao, S., Wang, L., & Leng, J. (2019) · BMC Cancer · doi:10.1186/s12885-019-6391-9 · Cited by 65
Couriel, D. R., Hicks, K., Giralt, S., & Champlin, R. E. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200011000-00011 · Cited by 65
DMXAA: An antivascular agent with multiple host responses
Baguley, B. C., & Ching, L. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03920-2 · Cited by 64
Cancer immunoediting and “spontaneous” tumor regression
Sengupta, N., MacFie, T. S., MacDonald, T. T., Pennington, D. J., & Silver, A. R. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.10.001 · Cited by 72
“2% were rendered free of clinical evidence of the disease for at least 20 years post-treatment [64].”
BackgroundKravchenko, J. S., Corsini, E., Williams, M. A., Decker, W. K., Manjili, M. H., Otsuki, T., Singh, N., Al‐Mulla, F., Al-Temaimi, R. A., Amedei, A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv033 · Cited by 63
Development of the PANVAC™-VF vaccine for pancreatic cancer
Petrulio, C., & Kaufman, H. L. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.1.9 · Cited by 60
“Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). Biotechnol. Ther. 4(3–4), 163–181 (1993).”
BackgroundProbst, P., Kopp, J., Oxenius, A., Colombo, M. P., Ritz, D., Fugmann, T., & Neri, D. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2946 · Cited by 73
“This issue may be particularly relevant for soft-tissue sarcomas, as these tumors tend to be highly sensitive to the action of TNF (5).”
BackgroundImmunotherapy in gastrointestinal cancers
Grierson, P. M., Lim, K., & Amin, M. A. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.05.01 · Cited by 61
“The initial observation suggesting that the immune system may play a role in modulating cancers was made nearly 125 years ago (49).”
BackgroundTuberculosis and cancer: parallels in host responses and therapeutic approaches?
Grange, J. M., Stanford, J. L., & Rook, G. A. W. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92542-2 · Cited by 56
The Human Response to Endotoxin
Lin, E., & Lowry, S. F. (1998) · Sepsis · doi:10.1023/a:1009890031293 · Cited by 61
Zhang, J., Lou, X., Jin, L., Zhou, R., Liu, S., Xu, N., & Liao, D. J. (2014) · Oncoscience · doi:10.18632/oncoscience.61 · Cited by 58
“Ironically, this socalled “Coley’s toxin” appears to be a better treatment than any currently used regimens since about 500 of the 1000 patients treated by Coley and others with this toxin showed significant tumor regression, according to the analyses by Coley’s daughter [106-109] and others [52,102,110,111].”
BackgroundMethodStarnes, C. O. (1992) · Nature · doi:10.1038/360023b0 · Cited by 53
Self-citationAn emerging role for nanomaterials in increasing immunogenicity of cancer cell death
Mishchenko, T. A., Mitroshina, Е. V., Balalaeva, I. V., Krysko, O., Vedunova, M. V., & Krysko, D. V. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.004 · Cited by 55
Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development
Liang, J., & Zhao, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0004 · Cited by 56
“In general, the current neoantigen prediction workflow of neoantigen-based therapeutic cancer vaccines shown in Figure 1 shares 6 main modules33,57: (1) next-generation sequencing of tumor tissue and HLA haplotype acquisition, (2) candidate neoantigen prediction using predictors, (3) neoantigen peptides validation by…”
BackgroundTumor microbiome metabolism: A game changer in cancer development and therapy
Zhou, X., Kandalai, S., Hossain, F., & Zheng, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933407 · Cited by 57
Antigen–immunostimulatory oligonucleotide conjugates: mechanisms and applications
Datta, S. K., Cho, H. J., Takabayashi, K., Horner, A. A., & Raz, E. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00149.x · Cited by 52
Lancaster, J. R. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113793 · Cited by 52
Escherichiacoli Nissle 1917 as a Novel Microrobot for Tumor-Targeted Imaging and Therapy
Liu, Q., Gai, Y., Chen, Y., Lan, X., & Jiang, D. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081226 · Cited by 50
“More than 100 years ago, bacteria were identified in human tumors [4,5].”
BackgroundMicrobiota in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Guan, D., Wang, Z., Li, X., Dong, S., Huang, J., & Zhou, W. (2023) · MedComm · doi:10.1002/mco2.417 · Cited by 50
“9 With the widespread use of antibiotics during and after surgery, the rate of postoperative infection has been effectively reduced, coupled with the routine use of antipyretics to eliminate the uncomfortable symptoms of an immune response.”
BackgroundHeat-shock proteins in infection-mediated inflammation-induced tumorigenesis
Goldstein, M. G., & Li, Z. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-5 · Cited by 47
“Conversely, in the 1700s cancer patients who cleared bacterial infections occasionally experienced remission of their established malignancies [9].”
BackgroundMethods for the development of tumor-targeting bacteria
Hoffman, R. M., & Zhao, M. D. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.916270 · Cited by 46
“In 1962, the Food and Drug Administration retracted Coley’s Toxins [3-12].”
BackgroundImpact of Fever-Range Thermal Stress on Lymphocyte-Endothelial Adhesion and Lymphocyte Trafficking
Appenheimer, M. M., Chen, Q., Girard, R. A., Wang, W., & Evans, S. S. (2005) · Immunological Investigations · doi:10.1081/imm-200064501 · Cited by 47
“In 1891, Coley treated a large cohort of sarcoma patients with a combination of heatkilled bacterial strains to induce high-grade fevers, and achieved a 10-year disease-free survival rate of over 25% (Starnes, 1992).”
BackgroundNanomedicine for improvement of dendritic cell-based cancer immunotherapy
Hashemi, V., Farhadi, S., Chaleshtari, M. G., Seashore-Ludlow, B. A., Masjedi, A., Hojjat‐Farsangi, M., Namdar, A., Ajoolabady, A., Mohammadi, H., Ghalamfarsa, G., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106446 · Cited by 48
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0588-4 · Cited by 50
Buckner, T. W., Dunphy, C. H., Fedoriw, Y. D., van Deventer, H. W., Foster, M. C., Richards, K. L., & Park, S. I. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.06.007 · Cited by 41
Cancer-testis antigens: the current status on antigen regulation and potential clinical use.
Lim, S. H., Zhang, Y., & Zhang, J. (2012) · PubMed Central · Cited by 41
Could COVID-19 induce remission of acute leukemia?
Kandeel, E. Z., Refaat, L., Abdelfatah, R., Samra, M., Bayoumi, A., Abdellateif, M. S., Abdelhady, H., Ali, M. K., & Khafagy, M. (2021) · Hematology · doi:10.1080/16078454.2021.1992117 · Cited by 44
“many times in the past in a trial performed by Starnes, for curing specific types of cancers like latestage sarcoma using streptococcal infection, which was the base of Coley’s toxins theory [10].”
BackgroundEngineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy
Tumas, S., Meldgaard, T. S., Vaaben, T. H., Hernandez, S. S., Rasmussen, A. T., Vazquez-Uribe, R., Hadrup, S. R., & Sommer, M. O. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-39365-2 · Cited by 48
Malignant melanoma—The cradle of anti-neoplastic immunotherapy
Koller, K. M., Wang, W., Schell, T. D., Cozza, E. M., Kokolus, K. M., Neves, R. I., Mackley, H. B., Pameijer, C. R., Leung, A. M., Anderson, B. E., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.010 · Cited by 43
“A modern compiling of the results with Coley’s Toxin showed that out of 104 patients with inoperable sarcoma, 50% demonstrated complete responses and more than 5 years of survival [19].”
MethodAbscopal effect: from a rare phenomenon to a new frontier in cancer therapy
Wang, X., Zhang, H., XinZhang, & Liu, Y. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00628-3 · Cited by 49
Programmable bacteria as cancer therapy
Dougan, M. L., & Dougan, S. K. (2019) · Nature Medicine · doi:10.1038/s41591-019-0513-4 · Cited by 38
Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy
Yang, Y., Feng, R., Wang, Y.-Z., Sun, H., Zou, Q., & Li, H. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.04.002 · Cited by 43
Current status of therapeutic vaccines for non-Hodgkin??s lymphoma
Hurvitz, S. A., & Timmerman, J. M. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000174040.52427.83 · Cited by 36
Zhu, Z., Liu, Q., Zhu, K., Wang, K., Lin, L., Chen, Y., Shao, F., Qian, R., Song, Y., Gao, Y., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.06.009 · Cited by 34
Sepich‐Poore, G. D., Guccione, C., Laplane, L., Pradeu, T., Curtius, K., & Knight, R. (2022) · BioEssays · doi:10.1002/bies.202100252 · Cited by 33
Zhang, P., Hu, X., Li, Z., Liu, Q., Liu, L., Jin, Y.-Y., Liu, S., Zhao, X., Wang, J., Hao, D., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj5465 · Cited by 39
“In addition, because Coley’s toxin is derived from heat-killed bacteria and bacterial ssDNA has been shown to be the major active component in Bacillus Calmette-Guerin treatment for cancer ( 4 , 48 , 49 ), SLFN11/9 might also be activated in this context.”
BackgroundBacterial extracellular vesicles for gut microbiome–host communication and drug development
Qian, D., Xu, P., Wang, X., Du, C., Zhao, X., & Xu, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.008 · Cited by 41
Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms
Sun, L., Chen, L., & Li, H. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.006 · Cited by 36
Cytokine gene transfer for cancer therapy
Podhajcer, O. L., Lopez, M. V., & Mazzolini, G. D. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.01.014 · Cited by 32
“Coley eventually prepared an extract of the microorganisms and treated over 800 cancer patients who showed regressions of their tumors that in some cases lasted for decades [4].”
BackgroundRole of Microbiome in Modulating Immune Responses in Cancer
Bose, M., & Mukherjee, P. (2019) · Mediators of Inflammation · doi:10.1155/2019/4107917 · Cited by 35
In pursuit of cancer metastasis therapy by bacteria and its biofilms: History or future
Adnan, M., Khan, S. A., Al-Shammari, E., Patel, M. B., Saeed, M., & Hadi, S. S. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.01.018 · Cited by 31
“carcinomas, sarcomas, melanomas, lymphomas, and myelomas successfully [10, 6].”
Influence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 37
“Furthermore, other studies have revealed that the intratumoral administration of bacteria or their antigens can paradoxically induce immune stimulatory effects, as observed in notable research based on Coley's toxins and bacterial cancer therapies [19,261].”
BackgroundEngineered bacteria: Strategies and applications in cancer immunotherapy
Zhang, S., Li, R., Xu, Y., Liu, R., Sun, D., & Dai, Z. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.11.001 · Cited by 35
“This conjugate structure produces a mutual inhibitory effect thereby controlling the LacZ signal output [ 6 ].”
Potential of DMXAA combination therapy for solid tumors
Baguley, B. C., & Wilson, W. R. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.5.593 · Cited by 30
Metadata
- Authors
- Starnes, C. O.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Starnes, Charlie O.
- Venue
- Nature
- Published
- 1992-05
- Volume
- 357
- Issue
- 6373
- Pages
- 11-12
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2005179058
- Cited by
- 284
- References
- 6
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 34 · 2023: 14 · 2022: 14 · 2021: 19 · 2020: 17 · 2019: 9 · 2018: 11 · 2017: 12 · 2016: 7 · 2015: 15 · 2014: 8 · 2013: 9 · 2012: 7
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- Coley's toxins, TNF-α, cancer therapy, patient selection, treatment efficacy
- MeSH terms
- Bacterial Vaccines, Humans, Sarcoma, Soft Tissue Neoplasms, Tumor Necrosis Factor-alpha, History, 19th Century, History, 20th Century
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.